On Demand Webinar

Establishment of Next Generation Pretreated PDX Models: A Tool for Precision Medicine

There is an urgent need for more clinically-relevant PDX models reflecting current patient populations and treatments that are failing in the clinic today due to drug resistance. Participate in this webinar to learn about Crown Bioscience's establishment and validation of pretreated PDX models, suitable for the development of next-generation therapeutics.

Watch Now

Watch this Webinar to Learn About:

• The establishment of pretreated PDX models with detailed treatment histories including KRAS inhibitors and checkpoint inhibitors.
  
  
• The characterization and validation of pretreated PDX models, including efficacy data
  
  
• Various preclinical applications (mouse clinical trials, databases, genomics, biomarker analysis) for the development and assessment of next generation oncology drugs.

Watch Now

About The Presenter:

Rekha Pal, PhD, Senior Director, Scientific Engagement

Dr. Pal is a trained cancer biologist with a focus on preclinical cancer therapeutics, immune-oncology, cancer signaling, and tumor microenvironment. She earned her PhD in Biochemistry from Central Drug Research Institute, India.

She joined the University of Pittsburgh as a postdoctoral researcher and moved onto research faculty. She has extensively worked in stem cell biology and translational cancer research using patient’s blood, tumor and bone marrow samples with a correlation of clinical data for the targeted biomarker identification with the drug treatment.

She joined National Surgical Adjuvant Breast and Bowel project (NSABP), a clinical trial supportive group to develop strategies for preclinical evaluation of test agents to support NSABP’s phase I/II clinical trials for colon and breast cancer. She also led the effort of organoids generation from the PDX tumor tissue to screen drugs or drug combinations as personalized medicine. Rekha represented NSABP as a translational research committee member on B-50 Katherine-B027938 Roche study.

Dr. Pal’s role at Crown Bioscience is to direct scientific engagement with pharmaceutical companies, academic scientists, and clients. She helps indecision making with the goal of high scientific input in study design and model execution. She exchanges scientific information for existing and new opportunities between Business Development and the scientific team, generates protocols, study design and proposals to define projects/ studies.